BackAgomAb Therapeutics N.V. American Depositary Shares Overview

AgomAb Therapeutics N.V. American Depositary Shares Other Current Liabilities

Latest other current liabilities for AGMB: $6.7M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$6.74M

Peer trimmed avg / median

Loading

AgomAb Therapeutics N.V. American Depositary Shares Other Current Liabilities History

Loading

AgomAb Therapeutics N.V. American Depositary Shares vs. peers: Other Current Liabilities Comparison

Loading

AgomAb Therapeutics N.V. American Depositary Shares Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) FAQ

AgomAb Therapeutics N.V. American Depositary Shares's other current liabilities stands at $6.7M as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether AgomAb Therapeutics N.V. American Depositary Shares's other current liabilities is expanding or contracting. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AgomAb Therapeutics N.V. American Depositary Shares's other current liabilities evolved across reporting periods, while the comparison chart places AGMB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. AgomAb Therapeutics N.V. American Depositary Shares's reading of $6.7M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.